WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside Chat Date: Friday, September 6, 2024 Fireside Chat Time: 10:00 AM ET Location: New York, NY H.C. Wainwright 26th Annual Global Investment Conference Fireside Chat Date: Monday, September 9, ...

WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced dosing of the first participants in the Phase 1 healthy volunteer clinical trial of VYD2311, a next generation monoclonal antibody (mAb) candidate for COVID-19. VYD2311 is a mAb with high in vitro neutralization potency shown against post-Omicron COVID-19 variants tested to date. The Phase 1 randomized, blinded, ...

New pseudovirus in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart) against KP.3.1.1, LB.1, and other SARS-CoV-2 variants tested Center for Disease Control reports KP.3.1.1 is the only major variant increasing in proportionality nationally Variants confirmed as susceptible to pemivibart in independent analyses contain key Q493E, s31del, and other mutations that are prominent in circulating SARS-CoV-2 variants Data submitted to FDA for anticipated timely updates to PEM ...

In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their everyday social interactions, participants receiving pemivibart experienced a 1.9% rate of confirmed symptomatic COVID-19 compared to an 11.9% rate for participants receiving placebo, an 84% relative risk reduction (nominal p= 0.000061) In immunocompromised participants, pemivibart demonstrated a rate of 3% of confirmed symptomatic COVID-19, an encouraging potential signal of protection during the assesse ...

Invivyd, Inc. (NASDAQ:IVVD) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Katie Falzone - VP, Corporate Controller Marc Elia - Chairperson, Board of Directors and Executive Committee Tim Lee - Chief Commercial Officer Bill Duke - CFO Robert Allen - Chief Scientific Officer Mark Wingertzahn - SVP of Clinical Development and Medical Affairs. Conference Call Participants Boran Wang - Guggenheim Securities Maxwell Skor - Morgan Stanley Operator Good day, and welcome to the Sec ...

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.11%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.38, delivering a surprise of 25.49%. Over the last four quarters, the company has surpasse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-40703 INVIVYD, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-1 ...

Exhibit 99.1 INVIVYD REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS • PEMGARDA™ launched commercially in Q2 2024 with $2.3 million of net product revenue • Notable acceleration of commercial results in early Q3 2024, with the anticipated peak fall/winter respiratory virus season approaching • New commercial leadership with Chief Commercial Of icer, Tim Lee, an experienced biopharmaceutical leader with demonstrated commercial success • Achieved Medicare and Medicaid coverage, ra ...

PEMGARDA™ launched commercially in Q2 2024 with $2.3 million of net product revenue Notable acceleration of commercial results in early Q3 2024, with the anticipated peak fall/winter respiratory virus season approaching New commercial leadership with Chief Commercial Officer, Tim Lee, an experienced biopharmaceutical leader with demonstrated commercial success Achieved Medicare and Medicaid coverage, rapid growth in commercial coverage across national and regional plans, and strong growth in infusion center ...

WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Wednesday, August 14, 2024, at 8:30 a.m. ET to discuss its financial results for the second quarter ended June 30, 2024, and recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session sh ...